QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.
The QurAlis strategy is to attack ALS one gene at a time by using a transformative system in which cells from ALS pa...
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.
The QurAlis strategy is to attack ALS one gene at a time by using a transformative system in which cells from ALS patients are used to model the disease in the lab to identify new drugs. QurAlis cofounders Kevin Eggan and Clifford Woolf, both Harvard professors, have pioneered this discovery technology for ALS.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.